Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649655 | 0.89 | CHRNB2 (0.37) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL2416817 | 0.89 | CHRNB2 (0.37) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL9873249 | 0.86 | ALDH1A1 (0.42) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL9873855 | 0.86 | ALDH1A1 (0.42) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL9874618 | 0.82 | KDM4E (0.39) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL16030794 | 0.79 | SSTR4 (0.36) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL16030790 | 0.79 | SSTR4 (0.36) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL16030792 | 0.79 | SSTR4 (0.36) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL22236155 | 0.79 | CHRNB2 (0.42) | SSTR4CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL7502974 | 0.78 | BTK (0.43) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911643-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| US-8278313-B2 | Macrocyclic spiro pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | SSTR4 4501/4885CHRNB2 4849/4885CHRNA4 4858/4885 |
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | DPYD, TYMS, TYMP | SSTR4 3659/4885CHRNB2 4872/4885CHRNA4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.